NCT04632758View on ClinicalTrials.gov

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

WX-0593 Tablets

tablets, 60 mg→180mg, QD

DRUG

crizotinib

Capsules, 250mg, BID

Trial Locations (1)

Unknown

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY